

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently amended) An ~~anti-viral~~ anti-fusogenic peptide-albumin conjugate comprising: an ~~anti-viral~~ anti-fusogenic peptide comprising a maleimide containing group and an amino acid sequence, wherein said sequence is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 534, SEQ ID NO: 535, SEQ ID NO: 536, SEQ ID NO: 537, SEQ ID NO: 538, SEQ ID NO: 539, SEQ ID NO: 540, and SEQ ID NO: 541, wherein said sequence exhibits an anti-viral and anti-fusogenic activity against human immunodeficiency virus (HIV) and said peptide is covalently bonded to cysteine 34 of albumin through said maleimide containing group to form said peptide-albumin conjugate wherein the ratio of peptide to albumin in said conjugate is 1:1.

2. (Cancelled)

3. (Cancelled)

4. (Currently amended) The ~~anti-viral~~ anti-fusogenic peptide-albumin conjugate of claim 1, wherein said amino acid sequence is SEQ ID NO: 1.

5. (Cancelled)

6. (Currently amended) An ~~anti-viral~~ anti-fusogenic peptide-albumin conjugate of claim 1, wherein said amino acid sequence is selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID

NO: 534, SEQ ID NO: 535, SEQ ID NO: 536, SEQ ID NO: 537, SEQ ID NO: 538, SEQ ID NO: 539, SEQ ID NO: 540, and SEQ ID NO: 541.

7.-18. (Cancelled)

19. (Currently amended) A composition for use in the treatment of acquired immune deficiency syndrome (AIDS) comprising, in a physiologically acceptable medium, an ~~anti-viral~~ anti-fusogenic peptide-albumin conjugate comprising an ~~anti-viral~~ anti-fusogenic peptide comprising a maleimide containing group and an amino acid sequence wherein said sequence is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 534, SEQ ID NO: 535, SEQ ID NO: 536, SEQ ID NO: 537, SEQ ID NO: 538, SEQ ID NO: 539, SEQ ID NO: 540, and SEQ ID NO: 541, wherein said sequence exhibits an anti-viral and anti-fusogenic activity against human immunodeficiency virus (HIV) and said peptide is covalently bonded to cysteine 34 of albumin through said maleimide containing group to form said anti-viral peptide-albumin conjugate, wherein the ratio of peptide to albumin in said conjugate is 1:1.

20. (Cancelled)

21. (Currently amended) The composition of claim 19, wherein said amino acid sequence is SEQ ID NO:1.

22. – 30. (Cancelled)

31. (Currently amended) The composition of claim 19, wherein said amino acid sequence is selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 534, SEQ ID NO: 535, SEQ ID NO: 536, SEQ ID NO: 537, SEQ ID NO: 538, SEQ ID NO: 539, SEQ ID NO: 540, and SEQ ID NO: 541.

32. – 35. (Cancelled)

36. (Currently amended) A composition comprising the ~~anti-viral~~ anti-fusogenic peptide-albumin conjugate of claim 1 in a physiologically acceptable medium.

37. (Cancelled)

38. (Currently amended) The composition of claim 36, wherein said amino acid sequence is SEQ ID NO:1.

39. (Currently amended) The composition of claim 36, wherein said amino acid sequence is selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 534, SEQ ID NO: 535, SEQ ID NO: 536, SEQ ID NO: 537, SEQ ID NO: 538, SEQ ID NO: 539, SEQ ID NO: 540, and SEQ ID NO: 541.

40. – 58. (Cancelled).

59. (Currently amended) The ~~anti-viral~~ anti-fusogenic peptide-albumin conjugate of claim 1, wherein said albumin is serum albumin.

60. (Currently amended) The ~~anti-viral~~ anti-fusogenic peptide-albumin conjugate of claim 59, wherein said albumin is human serum albumin.

61. (Currently amended) The ~~anti-viral~~ anti-fusogenic peptide-albumin conjugate of claim 1, wherein said amino acid sequence is SEQ ID NO: 3.

62. (Currently amended) The ~~anti-viral~~ anti-fusogenic peptide-albumin conjugate of claim 1, wherein said amino acid sequence is SEQ ID NO: 4.

63. (Currently amended) The ~~anti-viral~~ anti-fusogenic peptide-albumin conjugate of claim 1, wherein said amino acid sequence is SEQ ID NO: 5.

64. (Currently amended) The ~~anti-viral~~ anti-fusogenic peptide-albumin conjugate of claim 1, wherein said amino acid sequence is SEQ ID NO: 117.

65. (Currently amended) The ~~anti-viral~~ anti-fusogenic peptide-albumin conjugate of claim 1, wherein said amino acid sequence is SEQ ID NO: 118.

66. (Currently amended) The ~~anti-viral~~ anti-fusogenic peptide-albumin conjugate of claim 1, wherein said amino acid sequence is SEQ ID NO: 119.

67. (Currently amended) The ~~anti-viral~~ anti-fusogenic peptide-albumin conjugate of claim 1, wherein said amino acid sequence is SEQ ID NO: 534.

68. (Currently amended). The ~~anti-viral~~ anti-fusogenic peptide-albumin conjugate of claim 1, wherein said amino acid sequence is SEQ ID NO: 535.

69. (Currently amended) The ~~anti-viral~~ anti-fusogenic peptide-albumin conjugate of claim 1, wherein said amino acid sequence is SEQ ID NO: 536.

70. (Currently amended) The ~~anti-viral~~ anti-fusogenic peptide-albumin conjugate of claim 1, wherein said amino acid sequence is SEQ ID NO: 537.

71. (Currently amended) The ~~anti-viral~~ anti-fusogenic peptide-albumin conjugate of claim 1, wherein said amino acid sequence is SEQ ID NO: 538.

72. (Currently amended) The ~~anti-viral~~ anti-fusogenic peptide-albumin conjugate of claim 1, wherein said amino acid sequence is SEQ ID NO: 539.

73. (Currently amended) The ~~anti-viral~~ anti-fusogenic peptide-albumin conjugate of claim 1_x wherein said amino acid sequence is SEQ ID NO: 540.

74. (Currently amended) The ~~anti-viral~~ anti-fusogenic peptide-albumin conjugate of claim 1_x wherein said amino acid sequence is SEQ ID NO: 541.

75. (Currently amended) The composition of claim 19_x wherein said amino acid sequence is SEQ ID NO:3.

76. (Currently amended) The composition of claim 19_x wherein said amino acid sequence is SEQ ID NO:4.

77. (Currently amended) The composition of claim 19_x wherein said amino acid sequence is SEQ ID NO:5.

78. (Currently amended) The composition of claim 19_x wherein said amino acid sequence is SEQ ID NO:117.

79. (Currently amended) The composition of claim 19_x wherein said amino acid sequence is SEQ ID NO:118.

80. (Currently amended) The composition of claim 19_x wherein said amino acid sequence is SEQ ID NO:119.

81. (Currently amended) The composition of claim 19_x wherein said amino acid sequence is SEQ ID NO:534.

82. (Currently amended). The composition of claim 19_x wherein said amino acid sequence is SEQ ID NO:535.

83. (Currently amended). The composition of claim 19, wherein said amino acid sequence is SEQ ID NO:536.

84. (Currently amended) The composition of claim 19, wherein said amino acid sequence is SEQ ID NO:537.

85 (Currently amended) The composition of claim 19, wherein said amino acid sequence is SEQ ID NO:538.

86 (Currently amended) The composition of claim 19, wherein said amino acid sequence is SEQ ID NO:539.

87. (Currently amended) The composition of claim 19, wherein said amino acid sequence is SEQ ID NO:540.

88. (Currently amended) The composition of claim 19, wherein said amino acid sequence is SEQ ID NO:541.

89. (New) The anti-fusogenic peptide-albumin conjugate of claim 1, wherein the maleimide containing group is maleimidopropionic acid (MPA) or gamma-maleimide-butyralamide (GMBA).

90. (New) The anti-fusogenic peptide-albumin conjugate of claim 1, wherein the maleimide containing group is attached to the peptide via a linking group.

91. (New) The anti-fusogenic peptide-albumin conjugate of claim 90, wherein the linking group comprises polyethoxy amino acids.

92. (New) The anti-fusogenic peptide-albumin conjugate of claim 91, wherein the linking group is (2-amino) ethoxy acetic acid (AEA) or [2-(2-amino) ethoxy] ethoxy acetic acid (AEEA).

93. (New) The anti-fusogenic peptide-albumin conjugate of claim 1, wherein the maleimide containing group is attached to the peptide without a linking group.

94. (New) The composition of claim 19, wherein the maleimide containing group is maleimidopropionic acid (MPA) or gamma-maleimide-butyralamide (GMBA).

95. (New) The composition of claim 19, wherein the maleimide containing group is attached to the peptide via a linking group.

96. (New) The composition of claim 95, wherein the linking group comprises polyethoxy amino acids.

97. (New) The composition of claim 96, wherein the linking group is (2-amino) ethoxy acetic acid (AEA) or [2-(2-amino) ethoxy] ethoxy acetic acid (AEEA).

98. (New) The composition of claim 19, wherein the maleimide containing group is attached to the peptide without a linking group.